Maverick takeout adds T cell-engagers to Takeda’s solid tumor toolkit

The addition of Maverick’s T cell-engaging bispecifics technology to Takeda’s solid tumor toolkit is the latest move by the Japanese pharma to transform its once small molecule heavy pipeline to one built on multiple modalities. 

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) will pay up to $525 million in upfront and milestone payments for the Brisbane, Calif., biotech; the cost includes the pharma’s equity stake and Maverick Therapeutics Inc.’s debt. Maverick’s employees will join Takeda’s R&D organization...